NXY-059. Centaur.
Centaur and AstraZeneca are developing NXY-059, an alpha-phenyl-N-tert-butyl nitrone derivative, free radical trapping agent, for the potential therapy of reperfusion injury following stroke. Phase II clinical trials are ongoing, with phase III trials in acute stroke planned for initiation in early 2003.